

**Registration number 109034**

**Charity number 6775**

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' Report and Financial Statements**

**for the year ended 31 December 2017**

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Contents**

	<b>Page</b>
Directors and other information	1
Directors' report	2 - 6
Statement of Directors' Responsibilities	7
Independent Auditors' report to the members	8 - 10
Income and expenditure account	11 - 12
Balance sheet	13
Statement of Changes in Funds	14
Statement of Cashflows	15
Notes to the financial statements including Statement of Accounting Policies	16 - 34

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors and other information**

**Patron:** Michael D Higgins - President of Ireland

**Management Council - Company Directors & Project Director**

Directors	Paul Downes	
	Mark Mitchell	
	Austin O'Carroll	
	Edward Matthews	
	Roderick Malachy Maguire	
	Brian Patrick Dalton	
	Alice O'Flynn	
	Greg Ward	
	Catherine Comiskey	Appointed 31 May 2017
	Jack Nolan	Appointed 31 May 2017

**Secretary** L & P Trustee Services Ltd

<b>Company number</b>	109034
<b>Registered Charity Number</b>	20013301
<b>CHY Number</b>	6775
<b>Eligible Charity Number</b>	0465

**Registered office & Head Office** 48 Middle Abbey Street  
Dublin 1

**Auditors** Donal Ryan & Associates  
Chartered Certified Accountants & Statutory Auditor  
32 Manor Street  
Dublin 7

**Bankers** Permanent TSB,  
12/13 Lower O'Connell Street  
Dublin 1

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2017**

The directors present their report and the audited financial statements for the year ended 31 December 2017.

**The Companies Act 2014**

The Companies Act 2014 commenced on 1 December 2015 and the financial statements have been prepared in accordance with the Act.

**Principal activity of the Company**

The principal activity of the company is the provision of direct services to people who use drugs in Ireland. We do this from a low-threshold and harm reduction ethos, meaning that we try to keep the barriers to accessing our services as low as possible, and that our focus is on reducing the broad harms that drug use causes to individuals, families, communities and broader society. The organisation currently provides services in the Mid-West and Dublin areas, and in the online environment. In addition, the organisation works both nationally and internationally on civil society involvement in drug policy and in advocating for progressive drug policy choices.

**Results for the year**

The results for the year are set out on page 11 - 12.

In 2017, Ana Liffey Drug Project had an income of 1,986,139 (2016 - €2,126,911). It had expenditure of 1,997,865 (2016 - €2,113,203 excl. exceptional expenses).

At the end of the year the company had Fixed Assets €849,108 (2016: €272,781), Current Assets of €597,773 (2016 €604,844) and Current Liabilities of €252,542 (2016: €247,887). The Net funds of the company amounted to €1,194,339 (2016: €629,738) and the directors are satisfied with the level of retained reserves at the year end. Of the net funds at year end €849,108 is attributable to capital funds (fully expended) and €- is attributable to restricted funds.

Against the backdrop of limited resources and insecurities over funding, it has continued to be difficult to plan or develop services. Nevertheless the company, with the aid of sound financial management and the support of both its staff and volunteers generated a satisfactory financial outcome.

**Structure, Governance and Management**

***Structure***

Ana Liffey Drug Project is constituted as a company limited by guarantee as set out under parts 1-15 of the Companies Act 2014 with a registered office at 48 Middle Abbey Street, Dublin 1. It was incorporated on 8 August 1985 and its registered number is 109034. The company's constitutional documents were last externally reviewed in 2014, and are publicly available from the Companies Registration Office website ([www.cro.ie](http://www.cro.ie)). The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding one Euro (€1).

***Governance***

The company is governed by a board of directors, and corporate governance and compliance support is provided by L & P Trustee Services. As of 31st December 2017, the company had 10 directors. A list of directors and the subgroups of the board on which they sit is listed on page 1. For the entirety of 2017, Mr. Edward Matthews was the Chairperson of the company, and L & P Trustee Services was the company secretary.

The board met on 6 occasions in 2017.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2017**

..... continued

There is a clear division of responsibility at the company with the Board retaining control over major decisions. The board of directors retain the overall responsibility for the strategic direction of the company in close liaison with the Chief Executive Officer. Ana Liffey Drug Project has a Governance & Human Resources Committee in place with defined terms of reference which details the procedures involved in the recruitment, nomination and appointment process of new directors to the company. The succession planning process ensures that there is an appropriate balance of skills, experience, independence and knowledge in place to enable the directors to discharge their respective duties and responsibilities effectively and to oversee the work of the company in line with the company's strategy.

Directors are appointed according to the provisions as set out in the Constitution (comprising the Memorandum and Articles of Association). The term of office of each director is for a period of four years and a director may not be re-appointed for more than two successive terms totalling a maximum of eight years.

There is a formal induction process for incoming board members, which includes the provision of an induction pack of board minutes, constitutional documents and financial information compiled by the company secretary, and induction meetings with the Chairperson and other key personnel as appropriate. On appointment, new directors receive an Induction Pack which introduces the directors to the work of the company and help familiarise themselves with board process, core roles and responsibilities of the board and board of directors.

Trustee training is provided on an annual basis to new directors as part of their induction process and provides directors with an understanding and working knowledge of the essential elements of good governance and adheres to the relevant legal and regulatory compliance, trustee training is also provided to the existing directors as part of their ongoing training.

Directors do not receive remuneration for their services; there were no transactions with the Directors during the year.

During 2017, we worked on our governance structures as we continued on our path to full compliance with the Governance Code. The aim of the Code is to determine and formulate standards of best practice in corporate governance. The process involves a thorough review and assessment of the charity's policies, procedures, systems and values. The objective is to ensure the company run effectively while increasing transparency to provide assurance to all stakeholders. Key achievements during the year included establishing board committees and reviewing and updating the terms of reference for existing committees.

As part of these process key achievements during the year included reviewing and updating Terms of Reference for the various Board Committees, drafting a Board Handbook and reviewing and updating the relevant policies for the company.

The work of the board is supported by the following committees, each of which has its own terms of reference:

- Governance and HR Committee
- Clinical Governance Committee
- Financial and Audit Committee

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2017**

..... continued

***Management***

While the board is ultimately responsible for the organisation and its activities, issues related to the day-to-day running of the business are delegated to the Chief Executive Officer and through that role to the staff team. The management and staff of the organisation carry on the activities of organisation in line with the policies and strategies set out by the board. During 2017, a strategic planning process was carried out with consultation input from a range of stakeholders including people who use our services, funders and staff members. This resulted in the production of a strategic plan for the period 2018-2020 - 'Safer From Harm' - which is available to download from our website. The organisation has a work plan directed towards progressing each of the actions under the strategic plan.

***Vision, Mission, Values and Activities***

Our vision is for a society where all people affected by problem substance use are treated with dignity and respect and have access to quality services. Correspondingly, our mission is to work with people affected by problem substance use and the organisations that assist them. We do this to reduce harm to individuals and society, and to provide opportunities for development of those individuals and organisations.

In carrying out our work, we work to a number of overarching values. These are set out in detail in our strategic plan; in short, Ana Liffey:

- neither promotes nor denounces substance use but seeks to respond to problems associated with it
- is pragmatic
- believes in rights and responsibilities
- aims to make a positive contribution to society

***Achievements and Performance in 2017***

From the point of view of the board, 2017 was a positive year for the Ana Liffey Drug Project despite the challenging external environment. In terms of direct service delivery with people who use drugs, we delivered direct services in the Midwest and Dublin Regions, where we have a number of teams focused on direct service delivery. Aside from service delivery, we continued our work on drug policy, participating in projects and forums at home and abroad. We also carried out a range of support and online activities through our online and digital services team. Finally, we also carried out work on governance as we work towards full compliance with the Governance Code. The following section sets out a summary of our main activities and performance in each area:

***Dublin Services***

The Assertive Case Management team provided case management services to 59 individuals who are entrenched in drug use, criminality and have complex needs. The open access provided services to 1,063 individuals in 2017. Additionally, 75 individuals received case management, 363 people attended treatment groups and 201 individuals used the needle and syringe programme. The North East Inner City ACMT commenced work on October 1st 2017 and was providing case management services to 18 people by the end of 2017.

***Mid-West Services***

In the Midwest 253 people were registered with the service in 2017. Of these, 93 individuals accessed our case management service and 120 people accessed our needle and syringe programme.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2017**

..... continued

***Online and digital services***

The Drugs.ie site had 1,392,022 unique visits in 2017. The team also supported 712 people through the Live Helper chat service.

The team also researched, designed and launched three drug trend campaigns in partnership with the Health Services Executive.

***Policy and Participation***

In 2017, we both saw work from previous years reach a conclusion, as well as building on our capacity and engagement with policy issues both domestically and internationally. In January 2017, we hosted the Dublin Drug Policy Summit, which focused on supervised injecting centres and the adoption of a harm reducing and rehabilitative approach to possession for personal use. It was attended by a number of key Irish policy makers, including Minister Paschal Donohoe TD and Minister of State Catherine Byrne TD, as well as a range of international experts. In May, our Patron, President of Ireland Michael D. Higgins, signed into law the Misuse of Drugs (Supervised Injecting Facilities) Act 2017. The organisation had taken a lead role in advocating for the enactment of this important legislation which creates the legal framework under which Supervised Injecting Facilities can operate in Ireland. Also in 2017, we continued our policy work in Europe, where we are represented on the Civil Society Forum on Drugs (CSFD), an expert group to the European Commission of 45 NGOs from across Europe working in the area of drug policy. We have been on the forum since 2015, and Chair the workgroup on civil society engagement with national drug policies. Our work in the area also includes participation in projects with European partners - we are involved in two such projects - one on civil society involvement in drug policy which is set to finish in late 2018, and one providing a range of activities to support the work of the CSFD, which will run to 2019. Returning to our domestic work, 2017 saw the launch of 'Reducing Harm, Supporting Recovery', the country's national drug strategy for the period 2018-2025. We played an active role in its development, sitting on focus groups and contributing through the appropriate structures. We welcome the new strategy and look forward to playing a part in its implementation. In terms of other participation, we continue to contribute actively to local, regional and national fora such as the Voluntary Drug Treatment Network and networks of Local and Regional Drug and Alcohol Task Forces in the areas in which we provide services.

***Events after the Balance Sheet Date***

There have been no significant events affecting the company since the year-end.

***Principal Risks and uncertainties***

The Directors have identified that the key risks and uncertainties the company faces relate to the risk of a decrease in the level of government funding and the potential increase in compliance requirements in accordance with company, health and safety, taxation and other legislation;

The company mitigates these risks as follows:

- The company continually monitors the level of activity, prepares and monitors its budgets targets and projections. The company has a policy of maintaining adequate cash reserves;
- The company closely monitors emerging changes to regulations and legislation on an ongoing

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with health and safety of staff, volunteers, clients and visitors.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2017**

..... continued

**Payment of Creditors**

The directors acknowledge their responsibility for ensuring compliance with the provisions of the EC (Late Payment in Commercial Transactions) Regulations 2012. It is the company's policy to agree payment terms with all suppliers and to adhere to those payment terms.

**Government Department Circulars**

Ana Liffey Drug Project is compliant with relevant circulars including Circular: 44/2006 "Tax Clearance Procedures Grants, subsidies and Similar Type Payments" and DPE 022/05/2013 Circular: 13/2014 'Management of and Accountability for Grants from Exchequer Funds'.

**Accounting Records**

The directors acknowledge their responsibilities under Section 281 to 285 of the The Companies Act 2014 to keep proper books and records for the company. A number of measures have been taken by the directors to ensure compliance regarding proper accounting records with the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel and appropriate expertise and the provision of adequate resources to the financial function. The books of account of the company are maintained at the Registered Office and principal place of business.

**Statement on Relevant Audit Information**

In accordance with Section 330 of the The Companies Act 2014, so far as each person who was a director at the date of approving this report is aware, there is no relevant audit information, being information needed by the auditor in connection with preparing its report, of which the auditor is unaware. Having made enquiries of fellow directors and the group's auditor, each director have taken all the steps he/she is obliged to take as a director in order to make himself/herself aware of any relevant audit information and to establish that the auditor is aware of the information.

**Auditors**


In accordance with Section 383 (2) of The Companies Act 2014, the auditors, Donal Ryan & Associates, Chartered Certified Accountants & Statutory Auditor will continue in office.

This report was approved by the Board on 30 May 2018 and signed on its behalf by

**Edward Matthews**  
**Director**



**Greg Ward**  
**Director**





**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' responsibilities statements**

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with Irish law and regulations.

Irish Company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with The Companies Act 2014 and accounting standards issued by the Financial Reporting Council including FRS 102 The Financial Reporting Standard applicable in the UK and Ireland (Generally Accepted Accounting Practice in Ireland). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as to the financial year end and of the profit or loss of the company for the financial year and otherwise comply with the The Companies Act 2014.

In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors' report comply with the The Companies Act 2014 and enable the financial statements to be audited.

They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


Where financial statements are to be published on the web, the directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

On behalf of the board

**Edward Matthews**  
**Director**



**Greg Ward**  
**Director**

 Page 7

**Date: 30th May 2018**

**Independent auditors' report to the members of  
Ana Liffey Drug Project  
(A Company Limited by Guarantee and not having a Share Capital)**

**Opinion**

We have audited the financial statements of Ana Liffey Drug Project for the year ended 31 December 2017, which comprises of the Income and Expenditure, the Balance Sheet, the Statement of Changes in Funds, the Statement of Cashflows and the related notes to the financial statements, including a summary of significant accounting policies set out in note 1. The financial reporting framework that has been applied in their preparation is Irish law and accounting standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland as modified by the Statement of Recommended Practice "Accounting and Reporting by Charities" effective 1 January 2015.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2017 and of its profit for the year then ended;
- have been properly prepared in accordance with Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014

**Basis of Opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard as issued by the Irish Auditing and Accounting Service Authority ("IAASA") Ethical Standard and the provisions available for small entities, in the circumstances set out in note 18 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact

We have nothing to report in this regard.

**Independent auditors' report to the members of Ana Liffey Drug Project (continued)**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Opinions on other matters prescribed by Companies Act 2014**

In our opinion, based on the work undertaken in the course of the audit:

- we have obtained all the information and explanations which we consider necessary for the purposes of our audit;
- the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited;
- the financial statements are in agreement with the accounting records;
- the information given in the Director's/Trustees Report is consistent with the financial statements; and
- the Director's Report has been prepared in accordance with the Companies Act 2014.

**Matters on which we are required to report by exception**

Based on the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

**Respective responsibilities of directors for the financial statements.**

As explained more fully in the Directors'/Trustees' Responsibilities Statement set out on page 7, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


A further description of our responsibilities for the audit of the financial statements is located on the IAASA website at:  
[http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf). This description forms part of our audit report.

**Independent auditors' report to the members of Ana Liffey Drug Project (continued)**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**The purpose of our audit work and to whom we owe our responsibilities**

This report is made solely to the company's members as a body in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters that we are required to state to them in the audit report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company or the company's members as a body for our audit work, for this report, or for the opinions we have formed.

Signed by:



**Donal Ryan FCCA AITF**

*For and on behalf of:*

**Donal Ryan & Associates**

**Chartered Certified Accountants & Statutory Auditor**

**32 Manor Street**

**Dublin 7**

Date:

30/5/18

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Statement of Financial Activities (including Income & Expenditure)**  
**for the year ended 31 December 2017**

		2017	2017	2017	2017	2016
		Restricted	Unrestricted			
		funds	General funds	Designated funds	Total	Total
Notes	€	€	€	€	€	€
<b>Income From:</b>						
<i>Incoming resources from generated funds:</i>						
Donations and fundraising income	3		117,501		117,501	106,747
Deposit Interest	3		646		646	1,090
<i>Incoming resources from charitable activities:</i>						
State Funding	3	1,610,530			1,610,530	2,012,188
Other Grants	3	257,462			257,462	6,886
Total Income		<u>1,867,992</u>	<u>118,147</u>	<u>-</u>	<u>1,986,139</u>	<u>2,126,911</u>
<b>Expenditure on:</b>						
Governance Costs	5		13,087		13,087	13,797
Direct Charitable Expenditure	5	1,867,992	116,786		1,984,778	2,099,406
Other Resources Expended			-		-	30,036
Total Expenditure		<u>(1,867,992)</u>	<u>(129,873)</u>	<u>-</u>	<u>(1,997,865)</u>	<u>(2,143,239)</u>
Net Income		<u>-</u>	<u>(11,726)</u>	<u>-</u>	<u>(11,726)</u>	<u>(16,328)</u>

The notes on pages 16 to 34 form an integral part of these financial statements.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Statement of Financial Activities (including Income & Expenditure)**  
**for the year ended 31 December 2017**

		2017	2017	2017	2017	2016
		Restricted	Unrestricted	Designated	Total	Total
	Notes	funds	funds	funds		
		€	€	€	€	€
Other recognised gains/(losses)	10			579,393	579,393	
Capital Reserve Amortised		-	-	3,066	(3,066)	-
Net Movement in Funds		-	(11,726)	576,327	564,601	(16,328)
Reconciliation of Funds						
Total Funds Brought Forward		-	356,957	272,781	629,738	373,285
Total Funds Carried Forward		-	345,231	849,108	1,194,339	629,738

The notes on pages 16 to 34 form an integral part of these financial statements.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Balance sheet**  
**as at 31 December 2017**

		2017		2016	
	Notes	€	€	€	€
<b>Fixed assets</b>					
Tangible assets	10		849,108		272,781
<b>Current assets</b>					
Stocks		5,933		7,776	
Debtors	11	64,967		170,144	
Cash at bank and in hand		526,873		426,924	
		<u>597,773</u>		<u>604,844</u>	
<b>Creditors: amounts falling due within one year</b>	12	<u>(252,542)</u>		<u>(247,887)</u>	
<b>Net current assets</b>			<u>345,231</u>		<u>356,957</u>
<b>Total assets less current liabilities</b>			1,194,339		629,738
<b>Net assets</b>			<u>1,194,339</u>		<u>629,738</u>
<b>Capital and reserves</b>					
Designated funds			849,108		272,781
General funds			<u>345,231</u>		<u>356,957</u>
<b>Total funds</b>			<u>1,194,339</u>		<u>629,738</u>

The financial statements were approved by the Board of Directors on ..... and authorised for issue on ..... They were signed on its behalf by :

**Edward Matthews**

**Director**

**Date:**

*Edward Matthews*  
30/05/2018

**Greg Ward**

**Director**

**30 May 2018**

*Greg Ward*

The notes on pages 16 to 34 form an integral part of these financial statements.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Statement of Changes in Funds**  
**for the year ended 31 December 2017**

<b>Analysis of Net Assets between Funds</b>	<b>General Funds €</b>	<b>Designated Capital Funds €</b>	<b>Total €</b>
<b>At 1 January 2017</b>	356,957	272,781	629,738
(Deficit) for the year	(11,726)		(11,726)
Transfer to/(from) Designated Funds	-	576,327	576,327
<b>At 31 December 2017</b>	<u>345,231</u>	<u>849,108</u>	<u>1,194,339</u>

The notes on pages 16 to 34 form an integral part of these financial statements.



**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Statement of Cashflows**  
**for the year ended 31 December 2017**

	Notes	2017	2016
		€	€
<b>Cashflow from operating activities</b>			
Cash generated from operations	13	99,949	(102,388)
<b>Net decrease in cash in the year</b>		99,949	(102,388)
Cash at bank and in hand less overdrafts at beginning of year		426,924	529,312
<b>Cash at bank and in hand less overdrafts at end of year</b>		<u>526,873</u>	<u>426,924</u>
Consisting of:			
Cash at bank and in hand		<u>526,873</u>	<u>426,924</u>

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

**1. Statement of accounting policies**

The audited financial statements have been prepared by Ana Liffey Drug Project in accordance with accounting standards issued by the Financial Reporting Council, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") as modified by the Statement of Recommended Practice "Accounting and Reporting by Charities" effective 1 January 2015. Previously the company applied FRS 102 but did not apply the Statement of Recommended Practice "Accounting and Reporting by Charities". As a result of the adoption of the FRS 102 Charities SORP in the current period a change in accounting policy was required so as to ensure compliance with the Charities SORP. Details of the change in accounting policy and the related adjustments are detailed in Note 2. The charity has applied the Charities SORP on a voluntary basis as its application is not a requirement of the current regulations for charities registered in the Republic of Ireland however it is considered best practice. As noted below, the directors consider the adoption of the SORP requirements as the most appropriate accounting practice and presentation to properly reflect and disclose the activities of the organisation.

Ana Liffey Drug Project is a Company Limited by guarantee and is a public benefit entity incorporated in Ireland with a registered office at 48 Middle Abbey Street, Dublin 1.

The significant accounting policies adopted by the Company and applied consistently are as follows:

**1.1. Basis of preparation**

The audited financial statements have been prepared on the going concern basis under the historical cost convention (as modified by the revaluation of certain tangible fixed assets) and comply with the financial reporting standards of the Financial Reporting Council (and promulgated by the Association of Chartered Certified Accountants) as modified by the Statement of Recommended Practice "Accounting and Reporting by Charities" effective 1 January 2015 and the Companies Act 2014 except for the entity invoking the true and fair view override with regard to the profit and loss and balance sheet formats in Schedule 3 of the Companies Act 2014 as permitted in Section 3.4 of FRS 102 and Section 291 (5) of the Companies Act 2014.

*Going concern*

Given the level of net funds the company holds the directors consider that there are no material uncertainties about the company's ability to continue as a going concern.

The audited financial statements are prepared in Euro which is the functional currency of the company.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**1.2. Changes in Accounting Policy**

In preparing the financial statements for the current year, the company has adopted the following policy change:-

***Revaluation of Freehold property***

The land and buildings of the company were revalued by Conerney Estate Agents, to an open market value basis reflecting existing use on 25 April 2018. The valuation was carried out in accordance with the SCS Appraisal and Valuation Manual. This valuation was in excess of the historic cost being carried in the accounts. As a result of this the directors took the decision to write back the accumulated depreciation (including €371,873 diminution in value accounted for in 2014) resulting in the property now being stated at its original historic cost.

***Donations in Kind***

Donated services and facilities are included at the fair value to the charity where this can be quantified. Donations in kind are included at their estimated value to the foundation in both revenue and expenditure in the year of receipt. Donated facilities are included as both income and expenses at the value to the charity where this can be quantified and a third party is bearing the cost. Where it is not practicable to measure the value of the resource with sufficient reliability the income is included in the financial period when the resource is sold. An asset is recognised only when those services are used for the production of an asset and the services received will be capitalised as part of the cost of an asset. Where it cannot be quantified the value is recognised when sold. The value of services provided by volunteers is included in these accounts at the equivalent rate of a paid employee.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**1.3. Income Policy**

Income consists of state funding and donations. These are included in the financial statements when received at headquarters. Incoming resources have been included in the financial statements only when realised or when the ultimate cash realisation of which can be assessed with reasonable certainty.

Grant income from Public Sector Bodies/Government Agencies and other sundry sources are either credited when receivable to the Income & Expenditure Account or are deducted from expenses which give rise to the grants. Expenditure grants are credited to the Income & Expenditure Account upon the recognition of the associated expense for which the grant was originally received.

**Donations in kind**

Donated services and facilities are included at the fair value to the charity where this can be quantified. Donations in kind are included at their estimated value to the foundation in both revenue and expenditure in the year of receipt. Donated facilities are included as both income and expenses at the value to the charity where this can be quantified and a third party is bearing the cost. Where it is not practicable to measure the value of the resource with sufficient reliability the income is included in the financial period when the resource is sold. An asset is recognised only when those services are used for the production of an asset and the services received will be capitalised as part of the cost of an asset. Where it cannot be quantified the value is recognised when sold. The value of services provided by volunteers is included in these accounts at the equivalent rate of a paid employee.

**1.4. Expenditure**

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates:

- Expenditure comprises those costs incurred by the company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
- Costs include governance costs associated with meeting the constitutional and statutory requirements of the company and include the audit fees and costs linked to the strategic management of the company.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**1.5. Tangible fixed assets and depreciation**

Tangible fixed assets are recorded at historic cost less accumulated depreciation. Cost includes prime cost, overheads and interest incurred in financing the construction of tangible fixed assets. Capitalisation of interest ceases when the asset is brought into use.

Cost includes prime cost, overheads and interest incurred in financing the construction of tangible fixed assets. Capitalisation of interest ceases when the asset is brought into use.

The company undertakes a review for impairment of a fixed asset if events or changes in circumstances indicate that the carrying amount of the fixed asset may not be recoverable. To the extent that the carrying amount exceeds the recoverable amount, that is the higher of net realisable value and value in use, the fixed asset is written down to its recoverable amount. The value in use of fixed assets is determined from estimated discounted future net cash flows.

**Depreciation**

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost less residual value, of each asset systematically over its expected useful life, as follows:

Land and buildings	-	Over estimated remaining useful life
Fixtures, fittings and equipment	-	20% Straight Line
Motor vehicles	-	20% Straight Line

The company's policy is to review the remaining useful economic lives and residual values of property, plant and equipment on an on-going basis and to adjust the depreciation charge to reflect the remaining estimated useful economic life and residual value. The directors are of the opinion that, having regard to estimated residual values (based on prices prevailing at the dates of acquisition or subsequent revaluation) and the estimated useful economic lives, any depreciation involved would not be material.

**1.6. Taxation**

No charge to current or deferred taxation arises as the charity has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, Charity No CHY 6775. The charity is eligible under the "Scheme of Tax Relief for Donations to Eligible Charities and Approved Bodies under Section 848A Taxes Consolidation Act, 1997" therefore income tax refunds arising from sponsorships exceeding €250 per annum are included in unrestricted funds. Irrecoverable value added tax is expended as incurred.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**1.7. Pensions**

Retirement benefits are met by payments to a defined contribution pension fund. Contributions are charged to the profit and loss in the year in which they fall due. The assets are held separately from those of the company in an independently administered fund. Differences between the amounts charged in the profit and loss account and payments made to pension funds are treated as assets or liabilities.

**1.8. Stock**

Inventories are stated at the lower of cost and net realisable value. Where stock is received in a non-exchange transaction, stock is valued at the fair value of the stock received that being the price the entity would have to pay if that stock were purchased on an open market basis. Cost is calculated on a first in, first out basis and includes invoice price, import duties and transportation costs. Net realisable value comprises the actual or estimated selling price less all further costs to completion or to be incurred in marketing, selling and distribution.

At the end of each reporting period inventories are assessed for impairment. If an item of stock is impaired, the identified inventory is reduced to its selling price less costs to complete and sell and an impairment charge is recognised in the profit and loss account. Where a reversal of the impairment is recognised the impairment charge is reversed, up to the original impairment loss, and is recognised as a credit in the income and expenditure account.

**1.9. Fund Accounting**

The following funds are operated by the organisation:

*Restricted Funds*

Restricted Funds, represent grants, donations and sponsorships received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the directors. Such purposes are within the overall aims of the company.

*Unrestricted Funds*

General Funds represent amounts which are expendable at the discretion of Directors in furtherance of the objectives of the charity and which have not been designated for other purposes. Such funds may be held in order to finance working capital or capital expenditure.

*Designated Funds*

Designated funds are unrestricted funds earmarked by the Management Committee for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**2. Transition to Charities SORP (FRS 102)**

Previously the company applied FRS 102 as its accounting framework but did not apply the Statement of Recommended Practice "Accounting and Reporting by Charities" effective 1 January 2015. As a result of adopting the Charities SORP (FRS 102) in the current period a change in accounting policy was required so as to ensure compliance with the Charities SORP FRS 102.

Under FRS 102 the company adopted an accounting policy to recognise all grants on an accruals basis as opposed to on a performance basis. However, under the FRS 102 Charities SORP all grants including capital grants should be recognised as income in the SOFA on a performance basis (i.e. when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably). Given that the Charities SORP (FRS 102) represents best practice for all charities as it seeks to provide information relevant to the understanding of the directors and the performance and financial position of the Charity the directors believe the change in accounting policy is required.

There were no adjustments required on transitioning to the Charities SORP (FRS 102) .

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**3. Income**

The total income of the company for the year has been derived from its principal activity wholly undertaken in Ireland.

	2017	2016
	€	€
<b>Source of Funding</b>		
State Funding (see below)	1,610,530	2,012,188
Restricted EU & Other Funding	257,462	6,886
Donations	101,776	106,034
Other Income	15,725	713
Investment income	646	1,090
	<u>1,986,139</u>	<u>2,126,911</u>
<b>Grants and Other State Funding</b>	€	€
HSE - Dublin North City (Core Funding)	633,200	633,204
HSE (NICDATF) (NIC-2.2)	71,900	71,904
HSE (NICDATF) (NIC-17)	161,900	161,904
HSE Social Inclusion (NSP)	20,000	20,000
HSE Social Inclusion (Poole Volunteer Programme)	20,000	20,000
Dublin Regional Homeless Executive (51MAS)	70,500	52,875
HSE Social Inclusion (DRUGS.ie)	75,000	75,000
Dublin City Council (ACMT)	31,425	-
HSE Dublin North City (ACMT)	100,000	104,996
HSE Social Inclusion (QSP)	60,000	59,996
HSE Social Inclusion (Emerging Trends)	15,000	15,000
HSE Midlands (CADS)	-	334,258
Midlands Regional DATF (M11)	-	125,861
Mid-West Regional DAF (MW-8L)	188,504	188,504
HSE Mid-West (Homeless Programme)	47,900	47,900
COSC (Media Awards)	-	7,875
Safetynet (Street Drinkers)	-	180
Probation Service	49,000	49,000
HSE Social Inclusion (Media Awards)	16,515	20,231
Drug Policy Unit (Media Awards)	10,000	-
National Lottery	-	11,500
Dublin City Council	-	12,000
NEIC	39,686	-
	<u>1,610,530</u>	<u>2,012,188</u>
<b>Restricted EU &amp; Other Funding</b>		
CSFD - European Union Funding	218,436	-
Stichting De Regenboog Groép	18,609	2,319
Open Society Foundations	20,417	4,567
	<u>257,462</u>	<u>6,886</u>



**Ana Liffey Drug Project**  
(A Company Limited by Guarantee and not having a Share Capital)

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**4. Income**

Income & Expenditure stated in compliance with DPE 022/05/2013 Circular: 13/2014 Management of and Accountability for Grants from Exchequer Funds'.

<u>State Funding</u>				
Agency	HSE Addiction Services Dublin North City	HSE Addiction Services Dublin North City	Dublin City Council	
Sponsoring Government Department	Department of Health	Department of Health	Department of Housing, Planning, Community & Local Government	
Grant Programme	Core Funding	Assertive Case Management Team	Assertive Case Management Team	
Grants received in the year	597,200	100,000	37,396	
Grants Outstanding at 31 December 2017	36,000	-		
Grant deferred from 2016	-	25,000		
Grant deferred to 2018	-	(25,000)	(5,971)	
Total Grant in the year €	633,200	100,000	31,425	
Expenditure in the year €	633,200	100,000	31,425	
Term	Expires 31 December 2017	Expires 31 December 2017	Expires 1 March 2018	
Received in year ended	31 December 2017	31 December 2017	31 December 2017	
Capital Grant	Nil	Nil	Nil	
Restriction on use	Service Provision	Service Provision	Service Provision	

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

Agency	<u>HSE Social Inclusion</u>	<u>HSE Social Inclusion</u>	<u>HSE Social Inclusion</u>
Sponsoring Government Department	Department of Health	Department of Health	Department of Health
Grant Programme	DRUGS.ie	Poole Volunteer Programme	Needle and Syringe Programme
Total Grant in the year €	75,000	20,000	20,000
Expenditure in the year €	75,000	20,000	20,000
Term	Expires 31 December 2017	Expires 31 December 2017	Expires 31 December 2017
Received in year ended	31 December 2017	31 December 2017	31 December 2017
Capital Grant	Nil	Nil	Nil
Restriction on use	Service Provision	Service Provision	Service Provision

Agency	<u>HSE Social Inclusion</u>	<u>HSE Social Inclusion</u>	
Sponsoring Government Department	Department of Health	Department of Health	
Grant Programme	Quality Support Programme	Emerging Trends	
Total Grant in the year €	60,000	15,000	
Expenditure in the year €	60,000	15,000	
Term	Expires 31 December 2017	Expires 31 December 2017	
Received in year ended	31 December 2017	31 December 2017	
Capital Grant	Nil	Nil	
Restriction on use	Service Provision	Service Provision	

**Ana Liffey Drug Project**  
(A Company Limited by Guarantee and not having a Share Capital)

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

Agency	DR Homeless Executive	HSE (North Inner City Drugs & Alcohol Task Force)	HSE (North Inner City Drugs & Alcohol Task Force)
Sponsoring Government Department	Department of Housing, Planning, Community & Local Government	Department of Health	Department of Health
Grant Programme	Homeless Services	NIC 2-2	NIC 17
Total Grant in the year €	70,500		71,900
Expenditure in the year €	70,500		71,900
Term	Expires 31 December 2017	Expires 31 December 2017	Expires 31 December 2017
Received in year ended 31 December 2017	Nil	Nil	Nil
Capital Grant	Service Provision	Service Provision	Service Provision
Restriction on use / Note			
Agency	Mid-West Regional- DAF	HSE Mid-West	Probation Service
Sponsoring Government Department	Department of Health	Department of Health	Department of Justice & Equality
Grant Programme	Drugs & Alcohol	Homeless Programme	Prison Groups
Total Grant in the year €	188,504		47,900
Expenditure in the year €	188,504		47,900
Term	Expires 31 December 2017	Expires 31 December 2017	Expires 31 December 2017
Received in year ended 31 December 2017	Nil	Nil	Nil
Capital Grant	Service Provision	Service Provision	Service Provision
Restriction on use			

**Ana Liffey Drug Project**  
(A Company Limited by Guarantee and not having a Share Capital)

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

Agency	HSE Social Inclusion	Drug Policy Unit	Dublin City Council
Sponsoring Government Department	Department of Health	Department of Health	North East Inner City Programme Office
Grant Programmes	Let's Talk about Drugs Media Awards	Let's Talk about Drugs Media Awards	NEIC Assertive Case Management Team
Grants received in the year €	15,000	10,000	55,000
Add Grant deferred from 2016	1,515	-	-
Less Grant deferred to 2018	-	-	(15,314)
Grant credited in Accounts €	16,515	10,000	39,686
Expenditure in the year €	16,515	10,000	39,686
Term	Expires 31 December 2017	Expires 31 December 2017	Expires 31 December 2017
Received in year ended	31 December 2017	31 December 2017	31 December 2017
Capital Grant	Nil	Nil	Nil
Restriction on use	Service Provision	Service Provision	Service Provision

**Ana Liffey Drug Project**  
(A Company Limited by Guarantee and not having a Share Capital)

Notes to the financial statements  
for the year ended 31 December 2017

..... continued

**European Union and Other Non-State Funding**

Agency	Stichting De Regenboog Groép	Open Society Foundations	CSFD - Civil Society Forum on Drugs
Sponsoring Government Department	N/A - European Union Funding	N/A	N/A European Union Funding
Grant Programmes	HOME/2015/JDRU/AG/DRUG	Global Drug Policy Programme	760099-CSFD-Just-2016-AG-DRUG
Grants received in the year €	709	3,065	331,984
Add Grant Deferred from 2016 €	26,848	17,352	-
Less Grant deferred to 2018 €	(8,948)	-	(113,548)
Grant credited in Accounts	18,609	20,417	218,436
Expenditure in the year €	18,609	20,417	218,436
Received in year ended	31 December 2017	31 December 2017	31 December 2017
Capital Grant	Nil	Nil	Nil
Restriction on use	Service Provision	Service Provision	Service Provision

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

<b>5. Expenditure on Charitable Activities</b>	<b>Charitable Activities</b>	<b>Governance Costs</b>	<b>Total</b>
	<b>€</b>	<b>€</b>	<b>€</b>
<b>Costs directly allocated to activities</b>			
Staff Costs	1,426,747	-	1,426,747
Staff Training	7,442	-	7,442
Facilitation, Health & Safety & Staff Support	47,387		47,387
Programme costs	291,773	-	291,773
Support Costs (See note 5)	208,420	-	208,420
Depreciation	3,066	-	3,066
Capital Reserve Amortised	(3,066)	-	(3,066)
Audit	-	3,936	3,936
Legal & Professional Fees	3,011	9,151	12,162
	<hr/>	<hr/>	<hr/>
Total 2017	<b>1,984,780</b>	<b>13,087</b>	<b>1,997,867</b>
	<hr/>	<hr/>	<hr/>
Total 2016	<b>2,100,039</b>	<b>13,164</b>	<b>2,113,203</b>
	<hr/>	<hr/>	<hr/>

**6. Expenditure on Charitable Activities**

Where support costs are attributable to a particular activity the costs are allocated to that activity. Where support costs are incurred to further more than one activity, they are apportioned between the relevant activities based on the below measures:

	<b>Charitable Activities</b>	<b>Total</b>
	<b>2017</b>	<b>2017</b>
	<b>€</b>	<b>€</b>
<b>Costs directly allocated to activities</b>		
Rent & rates	15,753	15,753
Insurance	42,280	42,280
Utilities	32,498	32,498
Cleaning & waste disposal	20,731	20,731
Repairs & Maintenance	8,938	8,938
Office costs	13,555	13,555
Fundraising & Advertising	1,213	1,213
IT & Computer Maintenance	41,350	41,350
Travel & Accommodation	32,001	32,001
Bank Charges	80	80
General Expenses	21	21
	<hr/>	<hr/>
	<b>208,420</b>	<b>208,420</b>
	<hr/>	<hr/>

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

<b>7. Operating deficit</b>	<b>2017</b>	<b>2016</b>
	<b>€</b>	<b>€</b>
Operating deficit is stated after charging:		
Depreciation and other amounts written off/(back) re: tangible assets	(576,327)	10,694
Auditors' remuneration	3,936	3,936
Legal Secretary - L & P Trustee Services Ltd	<u>9,151</u>	<u>9,861</u>
and after crediting:		
Capital grants amortised & transfers to Capital reserves	<u>576,327</u>	<u>(14,447)</u>

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**8. Employees**

**Number of employees**

The average monthly numbers of employees  
(including the directors) during the year were:

	2017	2016
Management & Administration	4	4
Operational	28	32
	<u>32</u>	<u>36</u>

**Employment costs**

	2017 €	2016 €
Wages and salaries	1,187,704	1,277,081
Social welfare costs	125,881	135,083
Other pension costs	17,752	18,083
	<u>1,331,337</u>	<u>1,430,247</u>

In addition to the above, Ana Liffey Drug Project benefited from the work of volunteers who it is estimated, provided services worth €95,410 (2016 : €104,311) based on equivalent costs.

The Charity has three employees whose total employee benefits (excluding employer pension costs) for the reporting period exceeds €60,000. A table has been prepared below to accompany the report as required under DPE 022/05/2013 Circular: 13/2014 along with the amount of the total employer pension contributions of the charity.

	2017 No. of Employees	2016
<b>Bands of €10,000 exceeding €60,000</b>		
€60,000 to €70,000	2	2
€70,000 to €80,000	-	-
€80,000 to €90,000	1	1
€90,000 to €100,000	-	-
€100,000 to €110,000	-	-
	<u>2017</u>	<u>2016</u>
<b>Employer Pension Contributions</b>	€	€
Total Employer Pension Contributions amount to	17,752	18,083



**Ana Liffey Drug Project**  
(A Company Limited by Guarantee and not having a Share Capital)

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**9. Directors remuneration and transactions**

The present membership of the board is listed on the 'Directors and other information' page.

No members of the board of directors received any remuneration during the year (2016 - Nil).

No director or other person related to the company had any personal interest in any contract or transaction entered into by the company during the year (2016 - Nil).

<b>10. Tangible fixed assets</b>	<b>Land and buildings freehold €</b>	<b>Fixtures, fittings and equipment €</b>	<b>Motor vehicles €</b>	<b>Total €</b>
<b>Cost</b>				
At 1 January 2017	843,993	131,672	53,840	1,029,505
At 31 December 2017	843,993	131,672	53,840	1,029,505
<b>Depreciation</b>				
At 1 January 2017	579,393	123,491	53,840	756,724
Revaluation	(579,393)	-	-	(579,393)
Charge for the year	-	3,066	-	3,066
At 31 December 2017	-	126,557	53,840	180,397
<b>Net book values</b>				
At 31 December 2017	843,993	5,115	-	849,108
At 31 December 2016	264,600	8,181	-	272,781

The land and buildings of the company were revalued by Conerney Estate Agents, to an open market value basis reflecting existing use on 25 April 2018. The valuation was carried out in accordance with the SCS Appraisal and Valuation Manual. This valuation was in excess of the historic cost being carried in the accounts. As a result of this the directors took the decision to write back the accumulated depreciation (including €371,873 diminution in value accounted for in 2014) resulting in the property now being stated at its original historic cost.

The cost of acquiring the freehold property was funded by way of Government grant in 2002 advanced through the then Northern Area Health Board who hold a charge over the property at 48 Middle Abbey street, Dublin 1 until the year 2022.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

<b>11. Debtors</b>	<b>2017</b>	<b>2016</b>
	<b>€</b>	<b>€</b>
Other debtors	36,000	146,490
Prepayments and accrued income	28,967	23,654
	<u>64,967</u>	<u>170,144</u>
<b>12. Creditors: amounts falling due within one year</b>	<b>2017</b>	<b>2016</b>
	<b>€</b>	<b>€</b>
<i>Other creditors</i>		
Trade creditors	16,090	47,592
Deferred Income	168,781	98,258
Accruals	34,562	66,059
<i>Taxation creditors</i>		
PAYE/PRSI	33,109	35,978
	<u>252,542</u>	<u>247,887</u>
<b>13. Reconciliation of Operating Surplus to Net Cashflow from Operating Activities</b>	<b>2017</b>	<b>2016</b>
	<b>€</b>	<b>€</b>
Net Incoming Resources	(11,726)	13,708
Depreciation	(576,327)	10,694
Decrease in stocks	1,843	1,021
Decrease in other debtors	105,177	(131,582)
(Decrease) in Account creditors	(31,502)	(479)
Increase in other creditors	36,157	48,733
Government grant released	576,327	(14,447)
Redundancies Midlands	-	(30,036)
Net cash generated from operating activities	<u>99,949</u>	<u>(102,388)</u>

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**14. Analysis of changes in net funds**

	Opening balance	Cash flows	Closing balance
	€	€	€
Cash at bank and in hand	426,924	99,949	526,873
<b>Net funds</b>	<u>426,924</u>	<u>99,949</u>	<u>526,873</u>

**15. Company Limited by Guarantee**

The company is one limited by guarantee not having a share capital. The liability of each member, in the event of the company being wound up is €1.

**16. Capital commitments**

There were no capital commitments at the year end.

**17. Pension costs**

The company operates a defined contribution pension scheme. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to €17,752 (2016 - €18,083).

**18. APB Ethical Standard - Provisions Available for Small Entities**

In common with many other businesses of our size and nature we use our auditors to prepare and submit returns to the Revenue Commissioners and assist with the preparation of the financial statements.

**19. Accounting Periods**

The current accounts are for a full year. The comparative accounts are for a full year.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2017**

..... continued

**20. Approval of financial statements**

The financial statements were approved by the Board on 30 May 2018.

**Ana Liffey Drug Project**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**The following pages do not form part of the statutory accounts.**